Published Date: 02 Mar 2023
When adults with cancer take many medications, including blood pressure medications, supplements, or over-the-counter medications such as immunosuppressants, more toxic antibiotics may occur and may lead to the need to avoid the cancer.
Read Full NewsImmune checkpoint inhibitors have been FDA-approved for head and neck cancer for a decade, but their use has only marginally increased among patients younger than 65.
As the first chemotherapy-free regimen to beat gemcitabine/cisplatin, perioperative enfortumab vedotin plus pembrolizumab could shift muscle-invasive bladder cancer care — but questions remain.
Belzutifan plus lenvatinib significantly improves outcomes vs single agent cabozantinib in patients with advanced RCC who progressed after anti-PD-(L)1 therapy, new data show.
1.
Tumor infiltration of major blood vessels, not metastasis, may be primary cause of cancer death
2.
The Predictive Power of Liquid Biopsy in Colon Cancer Outcomes Is Inconsistent.
3.
Research identifies nearly 200 potential breast carcinogens in food packaging materials
4.
Anticoagulation for 12 months has been found to improve outcomes in cancer patients with minor blood clots.
5.
Doxorubicin-Trabectedin Strategy Boosts Survival in Challenging Sarcoma
1.
CAR T + Ibrutinib in R/R Mantle Cell Lymphoma: Phase 2 TARMAC Study Insights
2.
Uncovering the Hidden Symptoms of Parathyroid Cancer in Women
3.
Survivin as a Key Regulator in Gynecological Cancers: Therapeutic and Prognostic Implications
4.
The Basics of Langerhans Cell Histiocytosis: Understanding a Rare Disease
5.
Oncology Trials Roadmap: From Drug Discovery to Delivery and Patient Access
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Understanding the causes of anemia in adults beyond nutritional deficiencies
2.
An Intro to The Multifaceted Advantages of CDK4/6 Inhibitors in HR+/HER2- Advanced Breast Cancer Clinical Studies.
3.
Evolving Space of First-Line Treatment for Urothelial Carcinoma- Case Discussion
4.
An Eagles View - Evidence-based discussion on Iron Deficiency Anemia- Important Points to Know
5.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part II
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation